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Abstract
The term myocardial infarction with non-obstructive coronary arteries (MINOCA) applies to patients who have
clinical evidence of AMI but coronary angiography reveals no coronary obstructions and an alternative diagnosis is not
possible. It is a heterogenous group of disease. Its prognosis, predictors of mortality and optimum management is
unclear. In this review, we present a disease overview for MINOCA including the clinical features, adopted deﬁnitions,
prevalence, diagnosis, treatment, and prognosis.
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1. Introduction

W

orldwide, acute myocardial infarction
(AMI) is associated with high mortality
[1,2]. The management of AMI has evolved over
the last few decades. Management strategies such
as early coronary angiography and catheter-based
reperfusion have changed the outlook in cases of
AMI. Early in 1980, DeWood et al. [3] demonstrated that ST-segment-elevation myocardial
infarction (STEMI) was associated with an
occluded epicardial artery in >90% cases, but this
was not the case with non-ST segment-elevation
myocardial infarction (NSTEMI) [4]. Although
obstructive coronary artery disease was evident in
a majority of the patients with NSTEMI, complete
occlusion was not a predominant feature. Historically, absence of obstructive lesions in coronary arteries on angiography in patients with
STEMI and/or NSTEMI triggered a diagnostic
dilemma which withheld any further investigations and treatment. The term myocardial
infarction with non-obstructive coronary arteries

(MINOCA) applies to patients who have clinical
evidence of AMI but coronary angiography reveals no coronary obstructions and an alternative
diagnosis is not possible. Our understanding of
MINOCA has evolved in the recent past yet many
uncertainties persist regarding its pathophysiology, management, and prognosis. In this review, we present a disease overview for MINOCA
including the clinical features, adopted deﬁnitions, prevalence, diagnosis, treatment, and
prognosis.

2. Deﬁnition
Various terminologies including MINOCA,
MINCA (Myocardial infarction with normal coronary arteries) [5] and INOCA (ischemia and no
obstructive coronary artery disease) [6,7] have been
used for AMI/acute coronary syndrome (ACS) with
normal or near normal coronary arteries. Pasupathy
et al. [8] proposed a new term ‘troponin-positive
non-obstructive coronary arteries (TP-NOCA)’ that
includes patients with coronary disorders resulting
in ischemic necrosis, and myocardial and noncardiac disorders resulting in myocardial injury.
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Regardless of the underlying cause, TP-NOCA refers to all conditions with elevated troponin levels.
MINOCA is a subset of TP-NOCA where myocardial ischemia, possibly due to plaque rupture or
coronary dissection, is the cause for myocardial
injury [9].
According to the 4th Universal Deﬁnition of MI,
MINOCA is AMI in the absence of obstructive coronary artery disease (<50% coronary artery stenosis)
on angiogram (Table 1) [10e13].
Angiographic features of non-obstructive coronary
disease include normal coronary arteries, minimal
luminal irregularities (<30% stenosis) and mild to
moderate coronary atherosclerosis (30e50%).

3. Prevalence
Available evidence in literature suggests 5e15%
prevalence of MINOCA [12,14]. This wide range in
prevalence is mainly attributed to differences in
study population and the heterogeneity in adopted
deﬁnitions. Reported prevalence may be even
higher in the era of high sensitivity cardiac troponin
assays. The VIRGO study [15] reported 11.1%
prevalence of MINOCA whereas the SWEDEHEART study [16] reported a 8.0% prevalence.
Another observational study in Japan reported a
prevalence of 10.2% [17]. When compared to MI in
patients with obstructive coronary artery disease
(CAD), higher prevalence of MINOCA was found in
younger patients (58.8% vs. 61.3%, p < 0.001) and in
females (43% vs. 24%, p < 0.001) [18]. MINOCA is
also predominant in patients presenting with nonSTEMI (78% vs. 51%, p < 0.0001) when compared to
AMI with obstructive CAD [19]. Similar ﬁndings
have been reported in other studies [15,20e22].

4. Clinical characteristics
Patients with MINOCA are less likely to have
traditional risk factors. Old age, male sex, obesity,
smoking, and diabetes are negative predictors of

Abbreviation list
AMI
ACS
ACEi
ARBs
CAD
CMR
ESC
INOCA

Acute myocardial infarction
Acute coronary syndrome
Angiotensin converting enzyme inhibitors
Angiotensin II receptor blockers
Coronary artery disease
Cardiac magnetic resonance
European Society of Cardiology
Ischemia and no obstructive coronary artery
disease
IVUS
Intravascular ultrasound
MINOCAMyocardial infarction with non-obstructive coronary arteries
MINCA Myocardial infarction with normal coronary
arteries
MRI
Magnetic resonance imaging
NSTEMI Non-ST segment-elevation myocardial infarction
OCT
Optical coherence tomography
STEMI ST-segment-elevation myocardial infarction
TP-NOCA Troponin-positive non-obstructive coronary
arteries

MINOCA while peripheral vascular disease, cerebrovascular disease, liver disease, renal disease and
malignancy were identiﬁed as positive predictors
[17]. Based on ﬁndings reported in different studies,
it seems MINOCA tends to affect young females
more often than men. Patients generally have fewer
or similar cardiovascular risk factors compared to
MI with obstructive CAD [15,17,18].

5. Diagnosis of MINOCA
MINOCA can present with ST-elevation MI
(STEMI) or non-STEMI (NSTEMI). MINOCA
should be considered as a working diagnosis when
there is no obvious cause at presentation for
elevated troponin. So, in the assessment, the ﬁrst
step is to exclude non-ischemic causes of an
elevated troponin level. A position paper on
MINOCA from the Dutch ACS working group of

Table 1. 4th universal deﬁnition of myocardial infarction.
Acute myocardial infarction includes the following criteria:
1. Acute myocardial injury with clinical evidence of acute myocardial ischemia, and
2. With detection of a rise and/or fall of cardiac troponin with at least one value above the 99th percentile upper reference limit, and
3. With at least one of the following:
- Symptoms of myocardial ischemia
- New ischemic changes on electrocardiogram
- Development of pathological Q waves
- Imaging evidence of new loss of viable myocardium or regional wall motion abnormality in a pattern consistent with an ischemic
etiology
- The identiﬁcation of a coronary thrombus by angiography or autopsy
Reference: Thygesen et al. (2018) [10].

the Netherlands Society of Cardiology [14] considered MINOCA as dynamic working diagnosis to
help clinicians to further evaluate the underlying
mechanism and individualized management of
patients with MINOCA. If coronary angiography
during a suspected AMI shows non-obstructive
coronary arteries and there is no obvious cause for
the clinical presentation/elevated troponin like
sepsis,
pulmonary
embolism,
hypotension,
myocarditis, then a working diagnosis of MINOCA
is used. Every effort must be made to determine
the speciﬁc cause as prognosis and management
vary according to etiology. To reveal the underlying
cause of MINOCA, the European Society of Cardiology (ESC) working group proposed a diagnostic algorithm which included a thorough
history, physical examination, laboratory testing,
imaging, and invasive investigations [13]. This
comprehensive approach should help physicians
to manage MINOCA in a patient more
appropriately.
Vasospastic angina, characterized by transient ST
changes during chest pain that respond to nitrates, is
caused by coronary artery spasm leading to transient
coronary artery obstruction [7]. When there is suspicion of coronary vasospasm as the cause of
MINOCA, coronary vasospasm provocation test
with ergonovine and acetylcholine should be
considered at the time of coronary angiography
whenever it is available. The diagnosis of vasospastic
angina has prognostic value as it is associated with
increased mortality [23]. Optical coherence tomography (OCT) or intravascular ultrasound (IVUS)
imaging helps to rule out plaque disruption as the
cause of MI in cases where coronary angiography
failed to show obstructive lesions. Invasive functional coronary angiography with a diagnostic
guidewire and adenosine test may be needed to
establish a conﬁrmatory diagnosis of epicardial
vasospastic and microvascular angina [7].
Coronary microvascular dysfunction, deﬁned as
increased in coronary blood ﬂow less than 2.5- fold
in response to adenosine, has been associated with
ACS. Coronary microvascular dysfunction may or
may not be associated with coronary artery or
myocardial diseases. It may also be associated with
interventional cardiac revascularization procedures.
The underlying pathophysiological mechanisms
include
coronary
plaque
erosion,
microembolization, autonomic imbalance, endothelial
dysfunction, inﬂammation, and vascular smooth
muscle abnormalities [24]. Microembolism from
mural thrombosis of a coronary plaque (whether
ﬁbrous cap rupture or erosion) may be an important
cause. This may lead to microvascular angina.
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Demonstration of slow coronary ﬂow on coronary
angiography is the marker of microvascular
dysfunction. Most of the symptoms in patients with
nonobstructive CAD may be due to coronary
microvascular dysfunction. Cardiac magnetic resonance imaging (MRI) can be done to detect a
microvascular obstruction. Functional imaging
including positron emission tomography and
myocardial perfusion imaging, and coronary
computed tomographic angiography can help
establish a diagnosis of coronary microvascular
dysfunction [7].
Congenital thrombophilia (Protein C deﬁciency,
Factor V Leiden) and acquired thrombophilia associated with connective tissue diseases and oral
contraceptive pills can lead to thrombotic occlusion
of coronary arteries. These account for 12% and 3%,
respectively for MINOCA without evidence of an
obstructive atheroma [25]. These are not common
but important entities as these need anti-thrombotic
therapy.
Cardiac magnetic resonance (CMR) plays a
pivotal role for the diagnosis of patients with
MINOCA. The utility of CMR imaging is its ability
to identify infarcted tissue by late gadolinium
enhancement imaging, inﬂamed tissue by T2
weighted imaging, and regional wall motion abnormalities. However, the diagnosis remains
inconclusive in a signiﬁcant number of patients. A
recent study by Lintingre et al. [26], demonstrated
high diagnostic value of high-resolution late gadolinium CMR in patients with MINOCA. Collste
et al. [5] have provided an important insight in the
assessment of MINOCA by performing CMR imaging. The CMR studies revealed myocarditis in
7% patients with a typical myocarditis infarct
pattern in 19%, and no signiﬁcant abnormality in
67% of MINOCA patients. Of particular signiﬁcance were myocarditis cases detected on CMR
imaging despite the clinically overt cases being
excluded from study. These ﬁndings support the
importance of CMR imaging in the assessment of
MINOCA and mandate this imaging modality as
essential in the evaluation of patients with
MINOCA.

6. Differential diagnosis
MINOCA is a heterogenous entity with a clinical
diagnosis of AMI. The diagnosis of MINOCA should
exclude other overt causes for elevated troponin
(Table 2). This may also include obstructive coronary artery disease like distal stenosis or occluded
small branches and non-ischemic causes for
myocardial injury.
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Table 2. Clinical conditions associated with elevated troponin levels.
Coronary
conditions

Non-coronary
cardiac conditions

Non- coronary non- cardiac
(non- ischemic) conditions

Plaque rupture or erosion
Coronary artery spasm
Spontaneous coronary dissection
Aortic dissection with coronary
artery involvement
Coronary microvascular disorder
Thrombophilia
Sympathomimetic agents

Myocarditis
Takotsubo cardiomyopathy
Cardiomyopathies
Cardiac trauma

Stroke
Pulmonary embolism
Sepsis
Adult respiratory distress
syndrome
End stage renal failure

Strenuous exercise
Tachyarrhythmias
Cardiotoxins

Plaque disruption is common in MINOCA and
comprises plaque rupture, plaque erosion and
calciﬁc nodules. It leads to MI by thrombus formation with transient complete arterial occlusion with
spontaneous thrombolysis or distal embolization
[27]. OCT or IVUS imaging may be helpful when
coronary angiography reveals nonobstructive CAD
to rule out plaque disruption as the cause of MI.
The diagnosis of coronary spasm is particularly
important as optimum therapy with calcium channel blocker can improve prognosis. Varying prevalence rates are reported for coronary spasm in
patients with MINOCA. Deyama et al. [28] reported
71.4% prevalence of coronary spasm in MINOCA
after acetylcholine provocation test. Similar prevalence (71.3%) of coronary spasm was reported in
another study [29]. On the contrary, the VIRGO
study [15] reported a prevalence of 3.7% for coronary spasm in MINOCA patients. Moreover, an
early detection can help to improve prognosis as
vasospasms are generally associated with transient
ischemia which may not lead to myocardial
necrosis.
Spontaneous coronary artery dissection may
sometimes appear as non-obstructive coronary artery disease on angiography and should be considered as a cause of MINOCA. Coronary embolism in
patients with thrombophilia may deceptively appear
as MINOCA on angiography. Coronary microvascular dysfunction usually presents as stable CAD
but may also present as ACS and be a cause of
MINOCA. Lastly, MINOCA may have an uncertain
origin.

7. Treatment
Patients with MINOCA represent a major therapeutic challenge. Management of MINOCA is based
on limited evidence and there are no prospective,
randomized, controlled trials. A study has shown
that use of renin-angiotensin system blockers and
statins has mortality beneﬁts in patients with
MINOCA [30]. Lindahl et al. [16] reported beneﬁcial

effects of statins and renin-angiotensin system
blockers in MINOCA patients. But dual antiplatelets
and beta-blockers failed to show signiﬁcant reduction in major cardiac events. Although it was an
observational study, it was the ﬁrst study to evaluate
secondary prevention strategy in large number of
patients (n ¼ 9466) with MINOCA. The ongoing
randomized MINOCA BAT trial (ClinicalTrials.gov
Identiﬁer: NCT03686696), designed to evaluate
beta-blockers and angiotensin converting enzyme
inhibitors (ACEi)/Angiotensin II receptor blockers
(ARBs) in MINOCA patients, should provide information on best treatment strategy for these patients.
In clinical practice, it may be reasonable to administer ACEi/ARBs, statins, and antiplatelet agents to
most patients with MINOCA. Optimum therapy
with calcium channel blockers is the treatment of
choice for coronary spasm in patients with vasospastic angina. There are currently no effective
therapies for microvascular dysfunction.

8. Prognosis
There are conﬂicting data regarding the prognosis
of MINOCA. Overall, the prognosis of MINOCA is
not very favorable. Available data should be interpreted with caution since the outcomes of MINOCA
depend on the underlying cause. Pasupathy et al.
[18] reported better prognosis in MINOCA patients
compared to AMI with obstructive CAD. In-hospital
mortality was 1.1% in the MINOCA group and 3.2%
in the AMI with obstructive CAD group (p ¼ 0.001)
whereas the 12-month mortality was 3.5% and 6.7%
(p ¼ 0.003), respectively. Another study reported
similar 1- and 12-month mortality in both MINOCA
and AMI with obstructive CAD (1 month: 1.1% and
1.7%, respectively, p ¼ 0.043; 12 month: 0.6% and
2.3%, respectively, p ¼ 0.68) [15]. Bainey et al. reported a lower 1-year composite of death and/or
reinfarction rate among MINOCA patients with no
angiographic evidence of CAD (3.9%) when
compared to MINOCA with stenosis <50% (36.1%)
(p ¼ 0.028) [31]. On the other hand, Smilowitz et al.

[32] reported favorable prognosis for patients with
MINOCA. In an analysis of a nation-wide, multicenter, prospective registry, Choo et al. [30] reported
comparable clinical outcomes both in patients with
MINOCA and in patients with MI-CAD. Patients
with MINOCA (n ¼ 396) and myocardial infarction
with obstructive CAD (n ¼ 10 871) showed no signiﬁcant differences for risks of cardiac death (Hazard ratio [HR], 0.82; 95% conﬁdence interval [CI],
0.53e1.28; p ¼ 0.38), noncardiac death (HR, 1.55;
95% CI, 0.93e2.56; p ¼ 0.09) and reinfarction (HR,
1.23; 95% CI, 0.65e2.31; P ¼ 0.38), incidence of allcause death (HR, 1.04; 95% CI, 0.74e1.45; p ¼ 0.83).
In an observational study on more than 9000
MINOCA patients, Nordenskjold et al. [33] reported
24% major adverse cardiovascular events (MACEs)
and 14% mortality during a mean follow-up of 4.5
years. The average time to readmission in patients
with MINOCA was 17 months and this was mainly
due to reinfarction. Another observational study in
elderly population in Japan [17], found poor shortterm prognosis in patients with MINOCA compared
to those with MI-CAD. A Korean registry reported
similar incidence of all-cause death in patients with
MINOCA and MI-CAD (9.1% vs. 8.8%; HR, 1.04;
p ¼ 0.83). The incidence of all-cause death was
lower in patients with positive vasospasm than in
those with negative vasospasm. Non-use of reninangiotensin system blockers (HR, 2.63; 95% CI,
1.08e6.25; p ¼ 0.033) and statins (HR, 2.17; 95% CI,
1.04e4.54; p ¼ 0.039) was a signiﬁcant predictor of
all-cause death in MINOCA patients [30]. Retrospective analysis of a multicenter trial showed that
patients with MINOCA had a higher adjusted risk of
mortality at 1 year compared with patients with
non-ST elevation MI (5.2% vs. 1.6%) [34]. Mortality
rates in patients with MINOCA are said to be
related to the type of atherosclerotic plaques (calciﬁed plaque 1.4%, mixed plaque 3.3%, non-calciﬁed
plaque 9.6%) [35]. In a systematic review (>36,000
patients in 44 studies), the annual mortality rate in
patients with MINOCA was 2% [36]. There was a
reduced ejection fraction and ST depression at
presentation. The use of beta blockers at follow up
were associated with poor long-term prognosis.
Patients with MINOCA are reported to have worse
short and long-term survival compared with people
in the general population when matched for age and
sex [37].

9. Conclusions
In evaluation of patients with MINOCA, a systematic approach should be used to establish
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underlying etiology/mechanism especially for conditions that have effective therapies. MINOCA
should not be considered as a benign condition and
should receive same attention as MI-CAD. Based on
available evidence in literature, it is reasonable to
consider antiplatelets, statins, ACEi/ARBs for
MINOCA patients and individualize the treatment
based on underlying mechanisms. Further randomized studies with adequate sample size are
required to evaluate the optimal therapies for patients with MINOCA.
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